Literature DB >> 7780969

Multiple genetic alterations in hamster pancreatic ductal adenocarcinomas.

K W Chang1, S Laconi, K A Mangold, S Hubchak, D G Scarpelli.   

Abstract

Pancreatic ductal adenocarcinomas induced in the Syrian golden hamster (SGH) by N-nitrosobis(2-oxopropyl)amine share many similarities with the human disease, including mutations of the K-ras oncogene. In vitro carcinogenesis studies with immortal SGH pancreatic duct cells indicate that neoplastic transformation in this system can occur without mutational inactivation of p53 suppressor gene. In this study we extend the genetic analysis of the in vivo SGH model to increase the number of cases analyzed for the status of K-ras and to determine further the spectrum of alterations involved; we have studied the status of the p53, DCC, and Rb-1 suppressor genes and the status of the mdm2 oncogene, which can involve p53 indirectly. The partial SGH-coding sequence of mdm2 and DCC was determined. K-ras mutation in the second position of codon 12 was present in 17 of 19 (90%) of tumors. Immunohistochemistry and single strand conformation polymorphism analysis showed no evidence of p53 mutation in 21 tumors. RNase protection assays showed overexpression of mdm2 in 5 of 19 (26%) tumors. Semiquantitative reverse transcription-PCR analysis showed a complete or partial loss of DCC expression in 10 of 19 (53%) neoplasms and of Rb-1 (42%) expression in 8 of 19 tumors when compared to matched controls. Deregulation of these genes appears to be significant in SGH pancreatic carcinogenesis as indicated by their frequencies. However, the fact that 6 tumors showed either only a K-ras mutation or the absence of alterations of the 5 genes analyzed indicates that additional as yet unstudied or unknown genes are also involved in SGH pancreatic duct carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7780969

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  Transgenic models of pancreatic cancer.

Authors:  Andrew M Lowy
Journal:  Int J Gastrointest Cancer       Date:  2003

2.  p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb.

Authors:  Berthold Gerdes; Annette Ramaswamy; Andreas Ziegler; Sven A Lang; Michael Kersting; Renate Baumann; Anja Wild; Roland Moll; Matthias Rothmund; Detlef K Bartsch
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

3.  Defect in the p53-Mdm2 autoregulatory loop resulting from inactivation of TAF(II)250 in cell cycle mutant tsBN462 cells.

Authors:  C Wasylyk; B Wasylyk
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

4.  K-ras and p53 mutations in hamster pancreatic ductal adenocarcinomas and cell lines.

Authors:  N Erill; M Cuatrecasas; F J Sancho; A Farré; P M Pour; F Lluís; G Capellá
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

Review 5.  K-Ras mutations and benign pancreatic disease.

Authors:  M Löhr; P Maisonneuve; A B Lowenfels
Journal:  Int J Pancreatol       Date:  2000-04

6.  MicroRNA-132 Plays an Independent Prognostic Role in Pancreatic Ductal Adenocarcinoma and Acts as a Tumor Suppressor.

Authors:  Yan Chen; Huiyun Zhu; Yuqiong Wang; Yingxiao Song; Pingping Zhang; Zhijie Wang; Jun Gao; Zhaoshen Li; Yiqi Du
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

7.  Experimental animal models of pancreatic carcinogenesis for prevention studies and their relevance to human disease.

Authors:  Mami Takahashi; Mika Hori; Michihiro Mutoh; Keiji Wakabayashi; Hitoshi Nakagama
Journal:  Cancers (Basel)       Date:  2011-02-09       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.